全文获取类型
收费全文 | 1267篇 |
免费 | 195篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 15篇 |
儿科学 | 93篇 |
妇产科学 | 14篇 |
基础医学 | 94篇 |
口腔科学 | 39篇 |
临床医学 | 158篇 |
内科学 | 527篇 |
皮肤病学 | 9篇 |
神经病学 | 39篇 |
特种医学 | 164篇 |
外科学 | 137篇 |
综合类 | 46篇 |
预防医学 | 49篇 |
眼科学 | 1篇 |
药学 | 34篇 |
中国医学 | 5篇 |
肿瘤学 | 48篇 |
出版年
2022年 | 3篇 |
2021年 | 11篇 |
2020年 | 6篇 |
2019年 | 6篇 |
2018年 | 35篇 |
2017年 | 42篇 |
2016年 | 37篇 |
2015年 | 34篇 |
2014年 | 36篇 |
2013年 | 62篇 |
2012年 | 30篇 |
2011年 | 30篇 |
2010年 | 65篇 |
2009年 | 57篇 |
2008年 | 45篇 |
2007年 | 60篇 |
2006年 | 43篇 |
2005年 | 41篇 |
2004年 | 24篇 |
2003年 | 25篇 |
2002年 | 20篇 |
2001年 | 26篇 |
2000年 | 19篇 |
1999年 | 16篇 |
1998年 | 63篇 |
1997年 | 58篇 |
1996年 | 62篇 |
1995年 | 54篇 |
1994年 | 34篇 |
1993年 | 46篇 |
1992年 | 30篇 |
1991年 | 31篇 |
1990年 | 30篇 |
1989年 | 28篇 |
1988年 | 39篇 |
1987年 | 35篇 |
1986年 | 31篇 |
1985年 | 19篇 |
1984年 | 17篇 |
1983年 | 22篇 |
1982年 | 6篇 |
1981年 | 21篇 |
1980年 | 13篇 |
1979年 | 8篇 |
1978年 | 5篇 |
1977年 | 12篇 |
1976年 | 14篇 |
1975年 | 8篇 |
1972年 | 3篇 |
1971年 | 2篇 |
排序方式: 共有1472条查询结果,搜索用时 15 毫秒
71.
72.
73.
74.
Choice of Vein‐Harvest Technique for Coronary Artery Bypass Grafting: Rationale and Design of the REGROUP Trial 下载免费PDF全文
Marco A. Zenati MD MSc J. Michael Gaziano MD MPH Joseph F. Collins ScD Kousick Biswas PhD Jennifer M. Gabany MSN CRNP CCRC Jacquelyn A. Quin MD MPH Jerene M. Bitondo PA‐C Faisal G. Bakaeen MD Rosemary F. Kelly MD A. Laurie Shroyer PhD Deepak L. Bhatt MD MPH 《Clinical cardiology》2014,37(6):325-330
The Randomized Endo‐vein Graft Prospective (REGROUP) trial ( ClinicalTrials.gov NCT01850082) is a randomized, intent‐to‐treat, 2‐arm, parallel‐design, multicenter study funded by the Cooperative Studies Program (CSP No. 588) of the US Department of Veterans Affairs. Cardiac surgeons at 16 Veterans Affairs (VA) medical centers with technical expertise in performing both endoscopic vein harvesting (EVH) and open vein harvesting (OVH) were recruited as the REGROUP surgeon participants. Subjects requiring elective or urgent coronary artery bypass grafting using cardiopulmonary bypass with use of ≥1 saphenous vein graft will be screened for enrollment using pre‐established inclusion/exclusion criteria. Enrolled subjects (planned N = 1150) will be randomized to 1 of the 2 arms (EVH or OVH) after an experienced vein harvester has been assigned. The primary outcomes measure is the rate of major adverse cardiac events (MACE), including death, myocardial infarction, or revascularization. Subject assessments will be performed at multiple times, including at baseline, intraoperatively, postoperatively, and at discharge (or 30 days after surgery, if still hospitalized). Assessment of leg‐wound complications will be completed at 6 weeks after surgery. Telephone follow‐ups will occur at 3‐month intervals after surgery until the participating sites are decommissioned after the trial's completion (approximately 4.5 years after the full study startup). To assess long‐term outcomes, centralized follow‐up of MACE for 2 additional years will be centrally performed using VA and non‐VA clinical and administrative databases. The primary MACE outcome will be compared between the 2 arms, EVH and OVH, at the end of the trial duration. 相似文献
75.
Diffusion in gel-enzyme-linked immunosorbent assay—a new serological test for leptospirosis 下载免费PDF全文
A new serological test, diffusion in gel-enzyme-linked immunosorbent assay (DIG-ELISA) was developed and compared with the microscopic agglutination test (MAT) for the serological diagnosis of leptospirosis. The results suggest that DIG-ELISA is a viable alternative to the MAT because of its simplicity, sensitivity, versatility and potential for standardisation. 相似文献
76.
77.
Nash RA; Pineiro LA; Storb R; Deeg HJ; Fitzsimmons WE; Furlong T; Hansen JA; Gooley T; Maher RM; Martin P; McSweeney PA; Sullivan KM; Anasetti C; Fay JW 《Blood》1996,88(9):3634-3641
The safety and potential efficacy of FK506 in combination with a short course of methotrexate (MTX) for the prevention of acute graft-versus- host disease (GVHD) after marrow transplantation from HLA-matched unrelated donors was evaluated in a single-arm Phase II study conducted at two centers. Forty-three patients, 15 to 54 (median 41) years of age, were transplanted for hematologic malignancies. Thirty-seven of 43 evaluable patients had evidence of sustained marrow engraftment. Five patients died before day 17 after transplantation. The median time to an absolute neutrophil count of > 0.5 x 10(5)/L was 21 (range, 14 to 30) days. Nephrotoxicity (serum creatinine concentration > 2 mg/dL or doubling of baseline) occurred in 32 patients (74% cumulative incidence during the first 100 days after transplant). Other adverse effects included hypertension (n = 27), hyperglycemia (n = 27), neurotoxicity (n = 9) and thrombotic thrombocytopenic purpura (n = 2). Severe veno- occlusive disease of the liver occurred in 9 (21%) of the 43 patients. Eighteen patients (42%) developed grades II to IV acute GVHD and five (12%) developed grades III to IV acute GVHD. Twelve of 25 evaluable patients developed extensive chronic GVHD within 1 year of marrow transplantation resulting in an estimate of the probability of developing this complication of 48%. The cumulative incidence of transplant-related mortality during the first 100 days was 37%. Kaplan- Meier estimates of disease-free survival at 2 years for good-risk, poor- risk, and all patients were 65%, 4%, and 32%, respectively. FK506 in combination with a short course of MTX appears active in preventing acute GVHD after marrow transplantation from unrelated donors. Further studies comparing the combination of FK506 and MTX with cyclosporine and MTX for the prevention of acute GVHD are warranted. 相似文献
78.
Screening and Treatment for Subclinical Hypertensive Heart Disease in Emergency Department Patients With Uncontrolled Blood Pressure: A Cost‐effectiveness Analysis 下载免费PDF全文
79.
80.
Anthony M Dart Jan Erik Otterstad Bridget-Anne Kirwan John D Parker Sophie de Brouwer Philip A Poole-Wilson Jacobus Lubsen 《European journal of echocardiography》2007,8(4):275-283
AIMS: To evaluate the relationship between echocardiographic cardiac function and outcome in patients with stable symptomatic angina. METHODS: Baseline echo left ventricular ejection fraction and volume data measured in a central laboratory was available for 7016 patients (92% of the total) participating in the ACTION trial (A Coronary disease Trial Investigating Outcome with Nifedipine GITS). Ejection fraction was also measured by investigators. Evaluation of the different echocardiographic variables was based on adjusted hazard ratios comparing the unfavourable limit of the 90% range of the variable concerned to the favourable limit. RESULTS: The centrally measured ejection fraction was the most powerful predictor of all-cause death (adjusted hazard ratio=2.5), myocardial infarction, any stroke or transient ischaemic attack and overt heart failure (adjusted hazard ratio=4.5). The addition of either end systolic volume or end diastolic volume to ejection fraction did not materially affect the power of prediction. Compared to the central ejection fraction measurement, the investigator-measured ejection fraction was a less powerful predictor for all outcomes considered. CONCLUSION: Routine echocardiography carefully analysed by standardised methods provides useful prognostic information in patients with stable angina, including for total mortality. 相似文献